Wird geladen...
Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation
Bortezomib is the first proteasomal inhibitor (PI) to be used therapeutically for treating relapse cases of multiple myeloma and mantle cell lymphoma. A proposed mechanism for its action is that it prevents the proteasomal degradation of proapoptotic proteins, leading to enhanced apoptosis. Although...
Gespeichert in:
| Veröffentlicht in: | Oncol Lett |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
D.A. Spandidos
2015
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4579903/ https://ncbi.nlm.nih.gov/pubmed/26622817 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2015.3545 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|